Amphastar Pharmaceuticals (AMPH) Total Current Liabilities (2016 - 2026)

Amphastar Pharmaceuticals has reported Total Current Liabilities over the past 13 years, most recently at $158.2 million for Q4 2025.

  • For Q4 2025, Total Current Liabilities fell 8.98% year-over-year to $158.2 million; the TTM value through Dec 2025 reached $158.2 million, down 8.98%, while the annual FY2025 figure was $158.2 million, 8.98% down from the prior year.
  • Total Current Liabilities for Q4 2025 was $158.2 million at Amphastar Pharmaceuticals, down from $205.2 million in the prior quarter.
  • Over five years, Total Current Liabilities peaked at $258.0 million in Q3 2023 and troughed at $94.9 million in Q4 2022.
  • A 5-year average of $158.6 million and a median of $147.6 million in 2024 define the central range for Total Current Liabilities.
  • Biggest five-year swings in Total Current Liabilities: skyrocketed 152.43% in 2023 and later plummeted 45.49% in 2024.
  • Year by year, Total Current Liabilities stood at $103.8 million in 2021, then dropped by 8.62% to $94.9 million in 2022, then skyrocketed by 137.62% to $225.4 million in 2023, then decreased by 22.91% to $173.8 million in 2024, then dropped by 8.98% to $158.2 million in 2025.
  • Business Quant data shows Total Current Liabilities for AMPH at $158.2 million in Q4 2025, $205.2 million in Q3 2025, and $176.4 million in Q2 2025.